High Graphics
|
Low Graphics
Thursday 2 July, 2009
Home
About Us
FeedBack
Contact Us
Latest Headlines
|
Word Search
Comment
J&J comes riding to Elan’s rescue
Johnson & Johnson has today taken what looks like a $1.5bn gamble on experimental drug bapineuzumab and the rest of Elan’s Alzheimer’s pipeline. In a surprising announcement the US group revealed that...
2 Jul 2009
Discovery Labs finds disappointment at end of the journey
After more than five years, four complete response letters and multiple conversations with the FDA over the approvability of its treatment for respiratory distress syndrome (RDS) in premature babies, ...
2 Jul 2009
Acorda's licensing deal misses the M&A mark
As widely expected Acorda Therapeutics today pulled a non-US licensing deal with Biogen Idec for Fampridine SR, its drug to improve walking speed and ability in MS patients, out of the bag, and for a ...
1 Jul 2009
AMAG poised to shoot from the blocks following Feraheme approval
The decision might have come at the third attempt and one day late, but AMAG Pharmaceuticals will certainly not be complaining. The FDA yesterday not only handed the company the gift of approval for i...
1 Jul 2009
1
2
3
What is this?
View Archive
Showing headlines from the
Past 7 Days
Retrieving...
Analysis
Sanofi-Aventis scores important approval goal with Multaq
The FDA’s approval of Multaq, for atrial fibrillation, could not have come at a better time for Sanofi-Aventis, whose shares have come under pressure recently amid concerns over whether insulin produc...
2 Jul 2009
Generic players continue to impress in the first half
With so much talk of patent cliffs and biosimilar regulatory pathways, 2009 is shaping up to be a boom time for investors in generic companies, a half-yearly analysis of stock performance by EP Vantag...
1 Jul 2009
Turning point for sales and R&D spend forecast for 2009
In keeping with recently published IMS data predicting a decline in worldwide pharmaceutical sales this year, latest consensus forecasts from EvaluatePharma (World Preview 2014) also reveals that 2009...
30 Jun 2009
Biocon signs latest in string of biosimilar deals
As US lawmakers slowly move towards finalising the framework for approval of biosimilars, deals in the commercial sector are gathering pace. Yesterday, Mylan and India’s Biocon announced a tie up to d...
30 Jun 2009
1
2
What is this?
View Archive
Showing headlines from the
Past 7 Days
Retrieving...
EventAnalyzer
EventAnalyzer: Daily Market Movers (1 July 2009)
2 Jul 2009
EventAnalyzer: Weekly Market Movers (to 26 Jun 09)
29 Jun 2009
What is this?
View Archive
Showing
the Most Recent Headlines
Retrieving...
Home
|
About Us
|
Feedback
|
Contact Us
|
Terms & Conditions
|
Privacy Policy
Register for a free trial
Related Links
Registered Users
Word Search
Enter your free-text query in the box below
Searching...